{"id":"enviomycin","rwe":[],"tags":[{"label":"enviomycin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J04AB06","category":"atc"},{"label":"Active","category":"status"},{"label":"Pulmonary tuberculosis","category":"indication"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antibiotics, Antitubercular","category":"pharmacology"},{"label":"Antitubercular Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"tuberactinomycin n","offLabel":[],"synonyms":["enviomycin","Tuberactinomycin N","enviomycin sulfate"],"timeline":[],"approvals":[],"brandName":"Tuberactinomycin N","ecosystem":[{"indication":"Pulmonary tuberculosis","otherDrugs":[{"name":"aminosalicylic acid","slug":"aminosalicylic-acid","company":"Consolidated Midland"},{"name":"bedaquiline","slug":"bedaquiline","company":"Janssen Therap"},{"name":"capreomycin","slug":"capreomycin","company":"Akorn"},{"name":"cycloserine","slug":"cycloserine","company":"Purdue Gmp"}],"globalPrevalence":1280000}],"mechanism":{"modality":"Small Molecule","drugClass":"enviomycin","explanation":"Imagine your body's cells are under attack by bacteria. Enviomycin is like a special tool that helps stop the bacteria from multiplying and causing harm. It does this by interfering with the bacteria's ability to grow and divide.","oneSentence":"Enviomycin works by inhibiting bacterial growth and replication.","technicalDetail":"Enviomycin is a small molecule that likely targets a specific bacterial pathway or enzyme, although the exact mechanism of action is currently unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3180","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ENVIOMYCIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ENVIOMYCIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:57:20.324859","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:07.019529+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"cycloserine","drugSlug":"cycloserine","fdaApproval":"1964-06-29","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"rifampicin","drugSlug":"rifampicin","fdaApproval":"1971-05-21","relationship":"same-class"},{"drugName":"rifamycin","drugSlug":"rifamycin","fdaApproval":"2018-11-16","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"rifabutin","drugSlug":"rifabutin","fdaApproval":"1992-12-23","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"rifapentine","drugSlug":"rifapentine","fdaApproval":"1998-06-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"capreomycin","drugSlug":"capreomycin","fdaApproval":"1971-06-02","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"enviomycin","indications":{"approved":[{"name":"Pulmonary tuberculosis","source":"DrugCentral","snomedId":154283005,"regulator":"FDA","prevalenceClass":"1-5 / 10 000","globalPrevalence":1280000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cycloserine","brandName":"cycloserine","genericName":"cycloserine","approvalYear":"1964","relationship":"same-class"},{"drugId":"rifampicin","brandName":"rifampicin","genericName":"rifampicin","approvalYear":"1971","relationship":"same-class"},{"drugId":"rifamycin","brandName":"rifamycin","genericName":"rifamycin","approvalYear":"2018","relationship":"same-class"},{"drugId":"rifabutin","brandName":"rifabutin","genericName":"rifabutin","approvalYear":"1992","relationship":"same-class"},{"drugId":"rifapentine","brandName":"rifapentine","genericName":"rifapentine","approvalYear":"1998","relationship":"same-class"},{"drugId":"capreomycin","brandName":"capreomycin","genericName":"capreomycin","approvalYear":"1971","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02365623","phase":"PHASE2","title":"An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-02-18","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":6,"completionDate":"2018-11-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010912","UNII":"XU299C23A2","CHEBI":"CHEBI:135872","INN_ID":"3577","UMLSCUI":"C0014405","ChEMBL_ID":"CHEMBL2146142","KEGG_DRUG":"D03278","DRUGBANK_ID":"DB08993","PUBCHEM_CID":"3032903","SECONDARY_CAS_RN":"53760-33-1","MESH_DESCRIPTOR_UI":"D004776"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":38,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J04AB06","allCodes":["J04AB06"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"","aiSummary":"Tuberactinomycin N is a protein modality. It is being studied in an exploratory clinical trial for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Japanese participants.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:07.019529+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}